An open label, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy study of INCB018424 when applied to patients with plaque psoriasis involving 2 - 20% body surface area (BSA).
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2012
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 06 Oct 2009 New trial record.